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Abstract
Background: Few HIV antiretroviral adherence interventions target patients before they start treatment, assess
adherence readiness to determine the timing of treatment initiation, or tailor the amount of adherence
support. The Supporting Treatment Adherence Readiness through Training (START) intervention, based on the
information-motivation-behavioral skills model of behavior change, is designed to address these gaps with the
inclusion of (1) brief pill-taking practice trials for enhancing pretreatment adherence counseling and providing
a behavioral criterion for determining adherence readiness and the timing of treatment initiation and (2) a
performance-driven dose regulation mechanism to tailor the amount of counseling to the individual needs of
the patient and conserve resources. The primary aim of this randomized controlled trial is to examine the
effects of START on antiretroviral adherence and HIV virologic suppression.
Methods/design: A sample of 240 patients will be randomized to receive START or usual care at one of two
HIV clinics. Primary outcomes will be optimal dose-taking adherence (>85 % prescribed doses taken), as
measured with electronic monitoring caps, and undetectable HIV viral load. Secondary outcomes will include
dose-timing adherence (>85 % prescribed doses taken on time) and CD4 count. Primary endpoints will be
month 6 (short-term effect) and month 24 (to test durability of effect), though electronic monitoring will be
continuous and a fully battery of assessments will be administered every 6 months for 24 months.
Discussion: If efficacious and cost-effective, START will provide clinicians with a model for assessing patient
adherence readiness and helping patients to achieve and sustain readiness and optimal treatment benefits.
Trial registration: ClinicalTrials.gov identifier NCT02329782. Registered on 22 December 2014.
Keywords: HIV, Antiretroviral, Adherence, Readiness, Intervention, Randomized controlled trial
Background
The success of HIV antiretroviral therapy (ART) remains
dependent on high adherence [1–4]. While regimens
have been simplified and are more forgiving, nonadher-
ence is still a problem unsolved because many patients
(40–70 %) have suboptimal adherence [5–7]. With the
emergence of treatment as prevention [8] and patients
starting ART earlier [9], often before having experienced
any acute or advanced disease, the public health risks of
nonadherence may be greater than ever. Studies suggest
that patients with earlier-stage disease are less adherent
to treatment [10, 11], and, if many patients are started
on treatment before they are ready to adhere well, there
is greater risk for an expanding community pool of re-
sistance and less than adequate suppression of viral load
and infectiousness to limit transmission. Treatment
guidelines continue to emphasize the need for patients
to be ready to adhere well before starting ART [9], but* Correspondence: gwagner@rand.org
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there are no established, reliable methods for determin-
ing pretreatment adherence readiness.
Most ART adherence interventions are designed to
help patients achieve and maintain adherence readi-
ness, but few target patients before they start treatment
or tailor the amount of adherence support [12]. The
Supporting Treatment Adherence Readiness through
Training (START) intervention is based on the
information-motivation-behavioral skills (IMB) model
of behavior change [13]. It includes (1) brief pill-taking
practice trials for enhancing pretreatment adherence
counseling and providing a behavioral criterion for de-
termining adherence readiness and the timing of treat-
ment initiation and (2) a performance-driven dose
regulation mechanism to tailor the amount of counsel-
ing to the individual needs of the patient and conserve
resources. In a pilot randomized controlled trial [14],
START had effects on both behavioral adherence and
virologic suppression, unusual even for effective ART
adherence interventions, which have typically improved
one but not both of these outcomes [15]. The small
sample size (N = 54) precluded adequate statistical
power, but effect size estimates were 0.22 (dose-taking
adherence), 0.75 (dose-timing adherence), and 0.41
(complete virologic suppression) over the first 6 months
of treatment, with the latter two far exceeding the aver-
age 0.19 effect size found in a recent meta-analysis of
ART adherence interventions that, like START, were
not focused solely on patients already demonstrating
adherence problems [12]. These promising results pro-
vide the rationale for the current, more rigorous, larger
controlled trial of START.
In the present study, we are evaluating the effects of
the START intervention on the primary outcomes of
dose-taking adherence and undetectable viral load in a
multisite randomized controlled trial, the protocol of
which this article describes in detail. The primary object-
ive of the study is to determine whether START is su-
perior to usual care in helping patients achieve optimal
(>85 %) dose-taking adherence, and complete viral sup-
pression (undetectable HIV viral load) 6 months (short-
term efficacy) and 24 months (long-term efficacy) after
starting ART.
If effective, START will provide clinicians with an
intervention that (1) informs providers and patients
when the patient is ready to adhere well and start treat-
ment, (2) enhances adherence readiness from the outset
of treatment through the full course of therapy, and (3)
tailors the amount of adherence support based on indi-
vidual patient needs and performance, thus more effi-
ciently using clinic resources, fostering better
acceptance from providers and patients, and increasing
the likelihood of successful program adoption and
dissemination.
Methods/design
Study design
In this multisite randomized controlled trial, we will
evaluate the effects of the START intervention on ART
adherence and HIV virologic suppression. We will re-
cruit 240 patients with HIV at two HIV clinics, with each
randomized to receive either START or usual care at a
1:1 ratio at each clinic (60 patients in each arm at each
site). Random assignment codes will be computer-
generated and placed in a sequential list that will be
maintained by the principal investigator. Assignments
will be issued to study coordinators once candidates
have enrolled and completed the baseline survey. The
randomization will be stratified by prior ART history
(naïve or experienced) and CD4 count (<350 vs. ≥350
cells/mm3) because of the influence that prior ART his-
tory may have on adherence and clinical outcomes, and
also due to our interest in determining whether early-
stage patients can adhere as well as other patients to
treatment. There is no way to blind the participants to
whether they are receiving the intervention; this could
potentially influence adherence performance and reten-
tion, as clients may feel more or less incentive to
perform well in light of whether they receive the inter-
vention. We do not see a way to prevent this potential
bias, nor do we have a way to distinguish such effects
from actual intervention effects; however, this limitation
will be cited in reports of study findings.
Primary outcomes will be optimal dose-taking adher-
ence (>85 % prescribed doses taken), as measured with
electronic monitoring caps, and undetectable HIV viral
load. Secondary outcomes will include dose-timing ad-
herence (>85 % prescribed doses taken on time) and
CD4 count. Primary endpoints will be month 6 (short-
term effect) and month 24 (to test durability of effect),
though electronic monitoring will be continuous and a
fully battery of assessments will be administered every
6 months for 24 months. See Fig. 1 for the flow of par-
ticipant procedures through the protocol. Participants
will be paid $30 for each completed assessment, as well
as a $50 bonus if they complete all five primary assess-
ments and $10 for each attended intervention session.
To limit attrition, contact information will be collected
at enrollment and verified at each follow-up visit. Fur-
thermore, the study coordinator will check with all study
participants at the midway point between surveys, which
will be timed to coincide with regular scheduled clinic
appointments.
The study protocol has been reviewed and approved
by institutional review board (IRB) at the University of
California, Los Angeles (UCLA), and a certificate of con-
fidentiality has been obtained from the National Institute
of Mental Health. Any protocol modifications will be
submitted to the IRB for review, and participants will be
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informed if warranted. The trial is registered with the
National Institutes of Health (NIH) ClinicalTrials.gov
registry and assigned the number NCT02329782.
Setting
The study will take place at St. Mary’s Comprehensive
AIDS Resource and Education Clinic in Long Beach, CA,
USA, and UCLA Clinical AIDS Research and Education
(CARE) Center. The St. Mary’s clinic serves over 1500 cli-
ents with HIV, of whom about 60 % are nonwhite and 85 %
are male. The UCLA CARE center has nearly 1300 clients
with HIV, of whom 83 % are male and 40 % are nonwhite.
Both clinics have highly productive research units that con-
duct primarily biomedical and therapeutics research. Both
research units have highly trained study coordinators who
are experienced in research ethics, evaluation procedures,
protocol implementation, and provision of adherence treat-
ment support and counseling (as part of research trials, not
usual care), and they will be trained to be the project’s site
coordinators and intervention counselors.
Screening
Eligible
Not eligible
Survey/Abstraction
RZ
Practice trials85+%?
Start ART
No
Yes
Start ART
Survey/Abstraction
Week 0
Weeks 2-
4
Week 12
Week 26 / Month 6
Week 52 / Month 12
Next routine care visit
Next routine care visit
Next routine care visit
Week 78 / Month 18
Week 104 / Month 
24
Sessions wks 2 & 4
Maintenance module: 
Session A (+ B/C if req)
Maintenance module: 
Session A (+ B/C if req)
Maintenance module: 
Session A (+ B/C if req)
Maintenance module: 
Session A (+ B/C if req)
Survey/Abstraction
Survey/AbstractionSurvey/Abstraction
noitcartsbA/yevruSnoitcartsbA/yevruS
Survey/AbstractionSurvey/Abstraction
MEMS download
MEMS download
MEMS download
MEMS download
MEMS download
CONTROLINTERVENTION
Fig. 1 Flowchart of study protocol. RZ randomized, ART antiretroviral therapy, MEMS Medication Event Monitoring System
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Study sample
Eligibility criteria include (1) patient and provider plan
to start or restart (not currently on ART) the patient on
ART; (2) patient has stable health status and no acute
opportunistic infections or medical conditions (including
acute HIV infection) that warrant starting ART immedi-
ately, as determined by the patient’s provider; (3) detect-
able HIV viral load at last test (within past 6 months);
(4) if CD4 count is <200 cells/mm3, patient is on
prophylactic medication to limit risks associated with
the intervention’s imposed delay in starting ART; (5) pa-
tient is age 18 years or older; and (6) patient speaks
English. Providers will inform eligible patients of the
study, and patients who interested in participating will
be referred to the study coordinator for consent pro-
cedures, eligibility screening, baseline survey, and
randomization. Written informed consent will be ob-
tained from all participants at enrollment. For control
patients, the baseline visit is scheduled for the same day
or within 1 week of the screening assessment. The base-
line visit for intervention patients will take place on the
same day as the last pretreatment intervention session
(once they achieve >85 % dose-taking adherence during
a practice trial).
We calculated the size of effects that this sample can
detect with 80 % power (two-tailed test) with regard to
the primary outcomes. On the basis of the pilot study
[14], we expect that 40 % of the control group will
achieve optimal (>85 %) dose-taking adherence and 45 %
will achieve undetectable viral load. With these expected
rates in the control group, together with estimates of
10 % and 30 % attrition at months 6 and 24, respectively,
our sample size of 240 will be powered to detect a 9 %
difference between the two arms with regard to both op-
timal dose-taking adherence and undetectable viral load
at both months 6 and 24.
Adherence interventions
Usual clinical care
Usual care procedures to enhance adherence at the
clinics will continue to be implemented for all partici-
pants. Strategies for assessing adherence readiness at the
study sites include educating the patient about the im-
portance of adherence, evaluating patient commitment
and motivation to adhere to treatment, and assessing
whether barriers to adherence need to be addressed be-
fore initiating treatment (e.g., unstable housing, sub-
stance abuse). Once ART is initiated, routine inquiries
about adherence occur at regular follow-up visits (once
or twice in the first month of treatment, and then every
3–6 months). What varies across individual patients is
the staff member who discusses these issues with the pa-
tient (e.g., nurse, physician, case manager) and the
amount of time spent on these issues. Structured,
systematic counseling protocols and practice trials are
not part of usual care. We will measure adherence sup-
port received by patients as part of usual care in the par-
ticipant surveys, as described below.
START intervention
START is a comprehensive program of adherence train-
ing based on the IMB model of health behavior [13],
which asserts that information about ART and the im-
portance of adherence is a prerequisite but in itself is in-
sufficient to alter behavior, and that motivation for
adherence and behavioral skills to adhere well and over-
come barriers are critical determinants of adherence.
Motivation is fed by beliefs that the medication will be
helpful (treatment efficacy) and confidence that one can
adhere even in difficult circumstances (adherence self-
efficacy). Behavioral skills such as problem-solving and
adherence self-monitoring help to identify adherence
barriers and effective solutions to these barriers. While
not emphasized in the traditional IMB model, the social
context in which adherence occurs and the support the
patient receives can be important to all three of these
components, both positively and negatively. One’s sup-
port network can be a source of information and can
transmit beliefs about treatment that affect motivation.
Social support can maintain or break down psycho-
logical well-being and psychosocial functioning, thereby
impacting the patient’s ability to develop and use behav-
ioral skills needed to adhere well. Each component of
the IMB model is present in the START components
and specific sessions, as shown in Table 1.
START consists of pretreatment (including practice
trials to determine readiness for and timing of ART initi-
ation), early treatment, and ongoing maintenance train-
ing (using a performance-based dose regulation
mechanism to tailor the amount and intensity) phases,
each of which is outlined below. Sessions are adminis-
tered to individual patients by the interventionist, who
will be a trained research coordinator with adherence
counseling experience (but who does not provide usual
care). Each session lasts approximately 30 minutes. Exer-
cises often involve completing worksheets or the use of
handouts, which are given to the patient to use as a ref-
erence at home. Sessions are structured and manualized
but still allow flexibility for tailoring the content of the
exercises to the needs of the individual patient. Figure 1
depicts the flow of participation through each phase of
the intervention.
Pretreatment training phase This phase is composed
of a series of up to four 1-week practice trials accompan-
ied by adherence counseling and a dose regulation
mechanism in which patients discontinue the practice
trials and initiate ART once >85 % dose-taking
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adherence is achieved in a single practice trial, thus
demonstrating adherence readiness. Using 85 % adher-
ence to define readiness is consistent with what the lit-
erature indicates is needed for optimal treatment
benefits with the new, more potent ART regimens [1–3].
With today’s common once-daily regimens, this thresh-
old allows the patient to miss one dose over the course
of the week and still meet the criteria for readiness. Early
exercises and sessions will be focused on enhancing mo-
tivation and confidence to help prepare the patient for
later skill-building exercises that may call for behavior
change to overcome adherence barriers.
Session 1 Following an introduction and description
of the ART regimen, the counselor will provide educa-
tion about concepts such as viral load, drug resistance,
and the importance of dose-timing to ensuring a con-
stant adequate drug level. The importance of being
ready to adhere well before starting treatment will be
emphasized. Motivational interviewing (MI) techniques
[16] will be used to help the patient develop or
strengthen positive attitudes toward treatment and ad-
herence, with the goal of improving adherence self-
efficacy and motivation to adhere well. Exercises will be
devoted to enhancing social support (reminders, trans-
portation to clinic, provide reinforcement for successful
adherence) provided by the patient’s social network. The
practice trial will be introduced as an opportunity to ex-
perience what it is like to follow the prescribed ART
regimen and to evaluate the patient’s readiness to start
treatment. The practice trial regimen will mimic what
the patient’s provider intends to prescribe. A 1-week
supply of vitamins, with the electronic monitoring cap
attached to one of the pill bottles, will be given to the
patient to complete over the coming week.
Sessions 2–5 The number of sessions depends on the
number of practice trials the patient needs to complete.
Electronically monitored adherence results during the
preceding week’s practice trial are reviewed with the pa-
tient. The electronic monitoring printout provides a
chronology graph that depicts exactly the time that
doses were taken each day. Good adherence is rein-
forced, and missed doses are identified, including any
patterns that may be apparent. Patients are asked to
identify barriers that contributed to missed or late doses,
and antecedents to these scheduled doses are discussed.
The stages of problem-solving are introduced (define the
problem, decide on a goal, generate a list of possible so-
lutions, compare and select a solution to try, plan the
implementation of the solution, evaluate the effective-
ness of the solution). MI techniques will be used, and
the patient will be encouraged to take a leading role in
identifying key barriers, coming up with potential solu-
tions, and evaluating his or her experience in using these
solutions, all of which are designed to maximize the pa-
tient’s feelings of autonomy and self-efficacy and in-
crease the likelihood that these strategies will be
successfully adopted.
If dose-taking adherence during the practice trial is
85 % or greater, the patient will be considered ready to
start ART, no further practice trials will be completed, and
ART will be prescribed. The specific ART regimen planned
for the patient will be reviewed. The patient will be asked
to describe his or her daily routine and optimal ways for in-
tegrating the medication doses into his or her daily life.
Doses will be connected with specific daily activities or be-
haviors so that these routinized activities can serve as re-
minder triggers for taking medication doses. Common side
effects associated with the specific antiretrovirals prescribed
will be discussed; side effect management handouts outlin-
ing possible strategies to manage specific side effects will be
reviewed; and the patient will be encouraged to identify
strategies that are feasible for to adopt if side effects occur.
Table 1 Mapping of the START intervention’s conceptual framework and session content
Model component Intervention component or mechanism Sessions
Information Provide information about HIV, ART, and the importance of
adherence for treatment success and limiting resistance
Pre-ART session 1
Motivation Discuss attitudes and beliefs regarding ART and adherence,
and use MI to reframe and build positive attitudes
Pre-ART session 1, early ART week 2, maintenance phase
Use of problem-solving and confidence rulers to improve
adherence self-efficacy and sense of autonomy
Each session after the first one
Behavioral skills Practice trials to practice adherence to planned regimen Pre-ART sessions
Review adherence results (self-management) Each session after the first one
Use problem-solving to identify adherence barriers and
generate and evaluate solutions to these barriers
Each session after the first one
Integrate regimen into daily routine Pre-ART session 2
Side effect management Early ART and maintenance
Social support Review source of social support (positive and negative) and
discuss ways to enhance support for adherence
Pre-ART session 1, early ART week 2, maintenance phase
ART antiretroviral therapy, MI motivational interviewing, START Supporting Treatment Adherence Readiness through Training
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If dose-taking adherence to the practice trial is
<85 %, the patient will be given another 1-week supply
of vitamins for the next practice trial and encouraged to
use the strategies identified in the session to overcome
adherence barriers during the coming week. Linking the
doses to routinized daily activities will be discussed. For
those who are unable to achieve 85 % adherence after
completing four practice trials, the decision whether to
start treatment will be left up to the patient and his or
her provider. Adherence results from the practice trials
are shared with the patient’s provider to assist in making
this decision. Similarly, adherence data once the patient
is on ART, but none of the survey data, will also be
shared with the provider.
Early treatment training phase Training sessions are
scheduled at weeks 2 and 4 following onset of ART to
help patients maintain a high level of adherence readi-
ness and self-efficacy once they start the actual ART
regimen. There is no dose regulation during this phase,
as all patients receive both sessions. Session content
revolves primarily around identification of barriers, reso-
lution of adherence barriers, and side effect manage-
ment. The exceptions to this rule are the components of
social support enhancement (week 2) and addressing at-
titudes toward treatment and adherence (week 4), which
will take place in only one session each.
Maintenance training phase The pre- and early-
treatment phases help patients to be ready to adhere
well at the beginning of treatment, but the skills needed
to sustain adherence readiness over the long term may
be quite different from those needed at initiation; hence
the need for ongoing support. Maintenance modules will
start at week 12 and thereafter at each routine clinic visit
scheduled by the primary care provider as part of usual
care, with the goal of helping patients sustain a high
level of adherence over the course of treatment. Each
module is composed of biweekly sessions and is dose-
regulated such that patients who achieve >85 % dose-
taking adherence during the prior month receive only
one session while others receive sessions until >85 % ad-
herence is achieved during the 2-week period preceding
each successive session. For example, if the patient’s ad-
herence from weeks 8 to 12 is 85 % or greater, then the
patient will receive just the training session at week 12
and not return until the next routine clinic visit. How-
ever, if the patient’s adherence is <85 %, the patient will
return for another session at week 14. The number of
these biweekly sessions will be capped at three within
each module. As with the pretreatment training, this
dose regulation mechanism allows for varying the
amount of training to the needs of the individual patient
and for more efficient use of limited clinic resources for
adherence support. The content of the maintenance
training sessions will be similar to that during the early-
treatment training phase, with continued emphasis on
identification and resolution of adherence barriers, side
effect management, and use of social support to help en-
sure commitment and motivation for long-term
adherence.
Intervention training, supervision, and monitoring of
fidelity Fidelity in intervention administration will be
achieved through training, supervision, and monitoring.
The intervention counselors will be research coordina-
tors experienced in coordinating HIV treatment re-
search, including provision of adherence support during
clinical trials. They are not involved in provision of usual
care, thus limiting any risk of contamination of the usual
care control. Training will include review of the manual,
extensive role-playing of session exercises, and use of
basic MI techniques. Sessions will be audiotaped and
reviewed by the supervisor, who will use them to give
feedback for improvement. The supervisor will listen to
each session of the first three intervention participants
of each counselor and then each session of every fifth
participant of each counselor. Feedback will be provided
and problem cases discussed during biweekly
supervision.
Measures
Below are descriptions of the primary and secondary
outcomes with regard to ART adherence, virologic sup-
pression, immune function and HIV care retention (see
Table 2). The survey assessment includes measures of
potential mediators of intervention effects (e.g., compo-
nents of the IMB model such as HIV knowledge, adher-
ence motivation and self-efficacy, as well as depression
and substance use), and potential moderators (e.g.,
demographics), but these are not described in detail
here; however, we do describe below our survey mea-
sures of adherence support received from HIV providers
as part of usual care. The survey will be facilitated using
computer-assisted self-interview technology, which auto-
matically stores survey responses; survey data files will
be stored on password-protected, encrypted files.
ART adherence
Adherence to one of the vitamins in the practice trials
for those in the intervention arm, and to one antiretro-
viral (with the most complex regimen) for all partici-
pants once ART is initiated, will be measured
electronically and continuously throughout the study
using the Medication Event Monitoring System (MEMS)
caps. MEMS caps house a microelectronic chip that re-
cords the date and time of each bottle-opening, enabling
a precise, objective assessment of the timing of each
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dose and the patient’s pattern of pill-taking. Participants
will be instructed to refill the bottle when removing the
last remaining dose, to use the bottle provided for the
monitored medication, and to remove only one dose at a
time when the medication will be ingested. Participants
do not always follow these instructions (e.g., removing
multiple doses at once or “pocketing,” or opening the
bottle without removing a dose), so we will assess this
via self-report using a “past 2 weeks” time frame at each
primary assessment and will adjust the number of pre-
scribed does taken during this time period, which has
been validated and shown to strengthen the relationship
between adherence and viral load [17]. We will ask pa-
tients to notify the coordinator if their provider changes
their ART regimen.
Data taken from the caps are downloaded into a soft-
ware file that calculates summary scores that include
percentages of prescribed doses taken (dose-taking ad-
herence) and prescribed doses taken within a specified
window of time (dose-timing adherence). For the ana-
lysis, we will examine both mean dose-taking adherence
and proportion with ≥85 % dose-taking adherence as
primary outcomes, as well as mean dose-timing adher-
ence and proportion ≥85 % dose-timing adherence as
secondary outcomes. We will also ask participants to
self-report the number of doses missed in the last week
and percentage of prescribed medications taken in the
last month, which will be used as secondary outcomes.
HIV care retention
At each survey assessment, clients are asked about their
number of HIV care provider appointments scheduled,
attended, and missed in the past 6 months.
Virologic suppression and immune status
Clients will be asked to provide informed consent for ac-
cess to medical record data, which we will use to access
HIV viral load and CD4 assay results from the clinic’s
electronic medical charts. These assays are performed
routinely as part of usual care at regular clinic visits,
which are scheduled every 3–6 months for patients on
ART. Undetectable viral load and change in log-
transformed mean viral load are primary outcomes;
change in CD4 count is a secondary outcome.
Assessment of usual care practices to enhance adherence
Participants will be asked at each follow-up assessment
whether a provider has engaged them in specific
adherence-related discussions. Participants will be asked
to “indicate whether or not your provider(s) discussed
the following with you to help you adhere to your ART
regimen during the last 6 months.” For example, “Did
your providers discuss with you how to reduce or over-
come any problems you’ve had in adhering to your ART
regimen?” Participants respond to each of six items
using a 3-point response scale, with 0 = “No, this was
never discussed”; 1 = “Yes, a little time was spent
discussing this”; and 2 = “Yes, a lot of time was spent
discussing this.”
Data safeguarding and monitoring plan
Only U.S. Food and Drug Administration–approved
antiretroviral medications prescribed and monitored by
the primary care providers as part of routine clinical care
will be used in the study. Thus, we do not anticipate any
medication-related adverse events beyond those seen in
routine HIV medical care. Any adverse medication
Table 2 Primary and secondary outcomes
Outcome measures Outcomes
Primary outcomes
HIV viral load (chart-abstracted HIV RNA) Undetectable viral load (binary) (primary)
Log change in viral load from baseline (continuous)
Dose-taking adherence (MEMS) Took at least 85 % of prescribed doses (binary) (primary)
Percentage of prescribed doses taken (continuous)
Secondary outcomes
Dose-timing adherence (MEMS) Percentage of prescribed doses taken in correct time window (±2 h for twice-daily
regimens and ±3 h for once-daily regimens) (continuous)
Took at least 85 % of prescribed doses on time (binary)
Dose-taking adherence (self-report) Percentage of prescribed doses taken in past 7 days (continuous)
Took at least 85 % of prescribed doses (binary)
Visual analogue scale rating from 0 % to 100 % adherence over past 30 days
Dose interruptions (MEMS data) Number of >48-h interruptions
Clinic attendance (chart abstract; self-report) Number of attended and missed clinic appointments in past 6 months
CD4 count (chart-abstracted) Change from baseline
MEMS Medication Event Monitoring System
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events that occur as part of usual medical care and
noted by study staff will be communicated with the par-
ticipant’s consent to their primary medical care provider.
Loss of confidentiality is a potential adverse event, and
we have set up several mechanisms to ensure confidenti-
ality of participants. The nature of any information that
may need to be disclosed to protect the participant or
others is included as part of the consent process.
A single independent monitor will be appointed to
oversee the study. To allow effective monitoring, the in-
dependent monitor will be provided with periodic re-
ports, which will include subject enrollment, subject
retention, the number of patients who drop out of the
study with reasons for dropping out, and a listing of all
adverse events that are plausibly related to study proce-
dures. Periodic reports will be provided to the independ-
ent monitor at 6-month intervals; however, adverse
events that are considered directly related to aspects of
study participation will be reported immediately to the
monitor, the IRB, and the NIH. After review of the peri-
odic reports, the independent monitor may ask for clari-
fication or additional information from the principal
investigator. After such information is provided, if re-
quested, the independent monitor will make a recom-
mendation regarding the continuation, modification, or
termination of the study. All communications from the
independent monitor will be shared with the IRBs and
the NIH.
We have set up several mechanisms to ensure the con-
fidentiality of data collected from the participants. All
paper files are stored in locked file cabinets, and elec-
tronic files are stored in password-protected, encrypted
files. Furthermore, both paper and electronic files are
identified only by a participant’s identification number.
Identifying information linking participants to their
study identification number is retained in a locked cabi-
net accessible only by the principal investigator and
study coordinator. The final dataset will reside with the
principal investigator.
Data analysis
The primary aim of the analysis is to determine whether
the START intervention is superior to usual care in
helping patients achieve optimal adherence and virologic
suppression in both the short and long term. Dose-
taking adherence and viral load are the primary out-
comes. Continuous adherence will be assessed for nor-
mality and transformed if needed; viral load data will be
log-transformed. Our primary analysis is based on an
intent-to-treat approach, with secondary analyses involv-
ing study completers. Attrition weights will be used to
account for dropouts, and all analyses will incorporate
design effects from this weighting in the calculation of
standard errors and tests of significance. Analyses will
be conducted to compare groups at months 6 and 24 to
assess short- and long-term effects.
In addition to simple between-group comparisons at
each time interval (baseline and months 6, 12, 18, and
24), we will conduct analysis of the trajectory of out-
comes. Longitudinal analyses will be performed, using
mixed effects models to examine differences in trajector-
ies of adherence and HIV viral load across the two
groups, controlling for patient characteristics. Linear
mixed effects models will be used for continuous out-
comes, while nonlinear mixed effects models will be
used for binary outcomes (e.g., took at least 85 % of pre-
scribed doses, undetectable viral load). Along with a
fixed linear term for time, a random subject-specific
intercept will be incorporated, with the appropriate co-
variance structure of the repeated measures being deter-
mined during analysis. Covariates added to the models
will include components of our conceptual IMB frame-
work and intervention (e.g., HIV knowledge, adherence
motivation, adherence self-efficacy), as well as correlated
process variables (e.g., number of practice trials com-
pleted, total number of sessions attended). To ad-
equately model longitudinal HIV viral load, which has a
high proportion of values below the limit of detection, a
Bernoulli/log-normal random effects mixture model
with left censoring will be used [18, 19]. Analysis of co-
variance will be used to define an effect size estimate in
the analysis of the primary outcomes and to provide
baseline adjustment to improve statistical power.
A fully specified statistical analysis plan will be written
before unmasking of the data. The article presenting the
primary findings from this study will follow the outline
provided in Additional file 1. Study findings will be dis-
seminated to researchers and clinicians via publications
and conference presentations and to study participants
via a mailed one-page summary of findings. Authorship
of published papers will follow established guidelines for
defining the level of contribution that warrants author-
ship. Public access to study data will be made available
upon request and review of registration of application.
Discussion
In this study, we will conduct a rigorous, controlled
evaluation of the innovative ART adherence intervention
START. Unlike most other ART adherence interventions
that target people who are already on ART [12, 15, 20],
START attempts to provide the field with an evidence-
based intervention that works with patients before they
start treatment to ensure adherence readiness before
initiation—an approach that is particularly timely as
more patients with early stage disease start ART and
may be less ready to adhere well.
An added innovation of START is highlighted in its
design, which features components that are lacking in
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most ART adherence interventions to date: (1) inclusion
of pretreatment, early-treatment, and ongoing mainten-
ance training phases; (2) use of brief practice trials for
determining adherence readiness and the timing of ART
initiation; and (3) inclusion of a dose regulation mechan-
ism that adjusts the amount of pretreatment and main-
tenance training based on the patient’s recent
adherence performance. START combines these fea-
tures with a goal of producing a robust and lasting ef-
fect on both adherence and clinical outcomes, as well
as to be sensitive to and consistent with community
practice, the limited resources available to most clinics
and providers (especially as more patients start ART),
and the wide range of adherence skills present among
patients. This flexibility and attention to individual pa-
tient needs should increase the acceptability of the pro-
gram to patients, providers, and clinic administrators,
thus improving the likelihood of future translation into
usual care.
Our pilot controlled trial of START revealed evidence
of the intervention’s potential promise, with medium to
large effects on both behavioral adherence and un-
detectable viral load [14]. If this larger, fully powered
controlled test of the intervention produces similar re-
sults, START will provide clinics with a model for a
“new-generation” adherence support program to assist
their patients in achieving optimal treatment outcomes.
Also, this may be the first study of an adherence inter-
vention with a 2-year intervention and follow-up
period, which will enable us to assess the intervention’s
long-term efficacy.
Trial status
Enrollment is active.
Additional file
Additional file 1: 2010 Consolidated Standards of Reporting Trials
(CONSORT) flow diagram of the trial. (DOC 46 kb)
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